Spiolto Respimat Provides Meaningful Quality of Life Improvements in COPD
New data from the Phase IIIb OTEMTO 1&2 trials show Spiolto Respimat provides consistent and clinically meaningful improvements in quality of life versus placebo in patients with chronic obstructive pulmonary disease (COPD).
For COPD patients, breathlessness, among other symptoms, limits their ability to keep active and has a negative impact on their daily lives. As there is no cure for COPD, improving quality of life is a major goal of treatment.
Furthermore, data also shows that Spiolto Respimat provides clinically significant improvements in breathlessness compared to placebo reflecting the meaningful quality of life benefits and consistent improvements in lung function, breathlessness and quality of life.
“The improvement in quality of life provided by Spiolto Respimat in these trials could make a noticeable difference to the daily activity of COPD patients and enable them to maintain a more independent life..essentially the data show that patients feel much better.” said Dave Singh, Professor of clinical pharmacology and respiratory medicine.